Cytoki Pharma Company Profile

Background

Cytoki Pharma, founded in 2019, is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark. The company is dedicated to pioneering a new class of medicines that harness interleukin-22 (IL-22) biology to improve outcomes for metabolic diseases, including obesity and type 2 diabetes, as well as conditions characterized by epithelial injury, such as inflammatory bowel disease (IBD). By leveraging the innate properties of IL-22, Cytoki aims to develop therapies that drive lasting disease modification through healthy weight loss and broader metabolic effects.

Key Strategic Focus

Cytoki's strategic focus centers on developing IL-22-based therapeutics to address significant unmet needs in metabolic and epithelial injury-related diseases. The company's lead program, CK-0045, is a lipidated IL-22 analogue designed to offer a differentiated treatment approach for obesity and type 2 diabetes. By optimizing the pharmacologic properties of IL-22 through lipidation technology, CK-0045 aims to provide a first-in-class therapy with potential applications across a broad range of metabolic conditions.

Financials and Funding

In May 2021, Cytoki Pharma secured a $45 million Series A financing round. The funding was led by Lundbeckfonden Emerge (Denmark), with participation from Seventure Partners (France), +ND Capital (Switzerland), and Ysios Capital (Spain). The capital is intended to support the development of CK-0045 through Phase 1 and Phase 2a clinical testing in IBD and to explore its therapeutic potential in other diseases characterized by epithelial tissue injury.

Pipeline Development

Cytoki's lead candidate, CK-0045, has demonstrated promising results in clinical trials:

Phase 1 Trial (July 2024): The study evaluated the safety, tolerability, and pharmacokinetics of CK-0045 in healthy participants and those with obesity. Results indicated exposure-dependent reductions in body weight, improvements in low-density lipoprotein (LDL) cholesterol, blood insulin levels, and insulin resistance. CK-0045 was well-tolerated, with mild skin reactions being the most common side effect.

Phase 2 Trial (Initiated November 2024): A 16-week randomized, double-blind, placebo-controlled study is underway to assess the efficacy, safety, and tolerability of CK-0045 in 90 patients with obesity and type 2 diabetes. The trial will evaluate outcomes such as weight loss, changes in HbA1c, insulin sensitivity, and lipid levels. Results are anticipated in the first half of 2026.

Technological Platform and Innovation

Cytoki's innovation lies in its development of lipidated IL-22 analogues:

Proprietary Technologies: The company utilizes lipidation technology to enhance the pharmacokinetic properties of IL-22, extending its circulation time and enabling subcutaneous delivery. This approach aims to create long-acting therapies with improved efficacy and patient compliance.

Scientific Methodologies: Preclinical studies have demonstrated that lipidated IL-22 induces dose-dependent reductions in body weight and blood glucose levels in murine models. These findings support the potential of CK-0045 as a novel treatment for metabolic diseases.

Leadership Team

Cytoki Pharma is led by a team of experienced professionals:

Rasmus Jorgensen, PhD – Founder and CEO

Anne Louise Kjølbye, PhD, MBA – Chief Development Officer

Martijn van de Bunt, MD, DPhil – Chief Scientific Officer

Anuj Madhok, PhD – Chief Business Officer

Dorte Waaben, MSc – Head of CMC

Karsten Skydsgaard, DVM, E*MBA – Head of Non-Clinical Development

Christian Friis – Clinical Project Leader

The leadership team brings deep expertise in IL-22 biology, lipidation technology, and the discovery and clinical development of novel drugs targeting metabolic diseases.

Competitor Profile

Market Insights and Dynamics

The global market for obesity and type 2 diabetes treatments is substantial and growing, driven by increasing prevalence and the need for effective therapies. Innovations targeting novel mechanisms, such as IL-22 modulation, are gaining attention for their potential to address unmet needs in this space.

Competitor Analysis

Key competitors in the metabolic disease therapeutic landscape include:

Novo Nordisk: A leader in diabetes care, Novo Nordisk offers a range of GLP-1 receptor agonists and insulin therapies.

Eli Lilly: Develops and markets various diabetes medications, including GLP-1 receptor agonists and SGLT2 inhibitors.

AstraZeneca: Provides treatments for type 2 diabetes, such as SGLT2 inhibitors and DPP-4 inhibitors.

While these companies focus on established pathways, Cytoki's IL-22-based approach offers a novel mechanism that may provide complementary benefits.

Strategic Collaborations and Partnerships

Cytoki Pharma has established significant partnerships to advance its pipeline:

Novo Nordisk: In-licensed a full program of therapeutic IL-22 variants from Novo Nordisk, providing a strong foundation for Cytoki's development efforts.

Investors: Secured funding from prominent investors, including Lundbeckfonden Emerge, Seventure Partners, +ND Capital, and Ysios Capital, to support clinical development and expansion initiatives.

Operational Insights

Cytoki's focus on IL-22 biology positions it uniquely in the metabolic disease treatment landscape. By targeting epithelial tissues involved in metabolic processes, the company aims to offer therapies with distinct mechanisms of action compared to existing treatments. This differentiation may provide competitive advantages in addressing unmet medical needs.

Strategic Opportunities and Future Directions

Looking ahead, Cytoki Pharma plans to:

Advance CK-0045: Complete the ongoing Phase 2 trial and, pending positive results, progress to Phase 3 studies to further evaluate efficacy and safety.

Expand Pipeline: Develop additional IL-22-based therapies targeting other metabolic diseases and conditions characterized by epithelial injury, such as IBD.